Your browser doesn't support javascript.
loading
Diagnosis and first-line treatment of non-small cell lung cancer in the era of novel immunotherapy: recommendations for clinical practice.
De Marinis, Filippo; Barberis, Massimo; Barbieri, Vito; Marchianò, Alfonso; Gasparini, Stefano; Migliorino, Maria Rita; Romano, Giampiero; Spinnato, Francesca; Vitiello, Fabiana; Gridelli, Cesare.
Afiliação
  • De Marinis F; a Thoracic Oncology Division , European Institute of Oncology , Milan , Italy.
  • Barberis M; b Massimo Barberis, Clinic Unit of Histopathology and Molecular Diagnostics , European Institute of Oncology , Milan , Italy.
  • Barbieri V; c Medical Oncology Unit, Mater Domini Hospital , Salvatore Venuta University Campus , Catanzaro , Italy.
  • Marchianò A; d Diagnostic and Interventional Radiology Department , Fondazione IRCCS Istituto Nazionale dei Tumori , Milan , Italy.
  • Gasparini S; e Department of Biomedical Sciences and Public Health, Polytechnic University of the Marche Region, Pulmonary Diseases Unit , Azienda Ospedaliero-Universitaria Ospedali Riuniti , Ancona , Italy.
  • Migliorino MR; f Oncological Pulmonary Unit , San Camillo-Forlanini Hospitals , Rome , Italy.
  • Romano G; g Division of Medical Oncology , 'Vito Fazzi' Hospital , Lecce , Italy.
  • Spinnato F; h Division of Medical Oncology , 'Cervello' Hospital , Palermo , Italy.
  • Vitiello F; i Department of Pneumology and Oncology , U.O.S.D. Day Hospital Pneumoncologico Azienda Ospedaliera dei Colli Monaldi , Napoli , Italy.
  • Gridelli C; j Division of Medical Oncology , 'S. G. Moscati' Hospital , Avellino , Italy.
Expert Rev Respir Med ; 13(3): 217-228, 2019 03.
Article em En | MEDLINE | ID: mdl-30640563
ABSTRACT

INTRODUCTION:

In the era of personalized cancer therapy, the sampling of adequate tumor tissue for histologic diagnosis and genomic profiling is crucial, not only at the initial diagnosis but also in the event of resistant and recurrent disease when sequential biopsies may be required to evaluate somatic mutations and histologic changes. Areas covered The identification of genetic driver alterations led to the selection of patients who are most likely to benefit from epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) and rat osteosarcoma (ROS-1) tyrosine kinase inhibitors; on the other hand, in the absence of oncogenic alterations, platinum-based doublet chemotherapy regimens were the cornerstone of treatment. However, the advent of immunotherapy has widely changed the first-line treatment. Expert commentary An Italian Experts Panel Meeting was held to discuss on recommendations for diagnosis (optimization of the cyto/histologic tumor sample issue and management of tissue to molecular evaluation) and immunotherapy as first-line treatment of patients with advanced non-small-cell lung cancer.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Imunoterapia / Neoplasias Pulmonares Tipo de estudo: Diagnostic_studies / Guideline / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Imunoterapia / Neoplasias Pulmonares Tipo de estudo: Diagnostic_studies / Guideline / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article